New Patents Expand Coverage for Imaging and Therapeutic Applications of Peregrine's Phospholipid-Targeting Technologies

7 September 2010, 5:00 am

TUSTIN, CA--(Marketwire - 09/07/10) - Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM - News ), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced the issuance of two U.S. patents providing protection for tumor vasculature imaging and antiviral applications of a broad range of phospholipid ...... Read More »

More Topics from "Articles"

• EVTN Files Patents for Oil Spill Recovery Technology
• Silence Therapeutics Issued New Patents Covering siRNA Sequences for RNA Interference Therapeutics
• Silence Therapeutics receives two patents for RNA interference therapeutics
• Utah patents for doors, syringes and radar
• Court rejects rivals' motion to void patents on Teva's Copaxone
• RIM Wants Billboards That Know How Fast You're Driving [Patents]
• RIM Patents Adaptive Roadside and Pedestrian Billboard Systems
• Trident Microsystems Announces Plans to License Foundational MEMC Patents
• Solar Patents at record in 2009-Shine on Solar edition of CEPGI